HighPass Biotech

HighPass Biotech is a biotechnology company focused on developing novel conditioning agents for hematopoietic stem cell transplantation. The company's lead technology involves a monoclonal antibody targeting CD117, designed to selectively deplete diseased or aged stem cells from the bone marrow niche without the toxicity of traditional chemotherapy or radiation. This approach aims to make stem cell transplants and gene therapies safer and more accessible for patients with hematologic malignancies and genetic disorders. HighPass Biotech was founded by researchers from Stanford University and was subsequently rebranded as Jasper Therapeutics to advance its clinical pipeline.